AU2020315388A1 - Methods useful in treating cancers harboring a KRAS or HRAS mutation or amplification - Google Patents
Methods useful in treating cancers harboring a KRAS or HRAS mutation or amplification Download PDFInfo
- Publication number
- AU2020315388A1 AU2020315388A1 AU2020315388A AU2020315388A AU2020315388A1 AU 2020315388 A1 AU2020315388 A1 AU 2020315388A1 AU 2020315388 A AU2020315388 A AU 2020315388A AU 2020315388 A AU2020315388 A AU 2020315388A AU 2020315388 A1 AU2020315388 A1 AU 2020315388A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- compound
- subject
- administering
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874474P | 2019-07-15 | 2019-07-15 | |
| US62/874,474 | 2019-07-15 | ||
| PCT/US2020/042162 WO2021011674A1 (en) | 2019-07-15 | 2020-07-15 | Methods useful in treating cancers harboring a kras or hras mutation or amplification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020315388A1 true AU2020315388A1 (en) | 2022-02-17 |
Family
ID=74211326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020315388A Abandoned AU2020315388A1 (en) | 2019-07-15 | 2020-07-15 | Methods useful in treating cancers harboring a KRAS or HRAS mutation or amplification |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220257599A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3999049A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022540921A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114364377A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020315388A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147588A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021011674A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102679204B1 (ko) * | 2021-02-10 | 2024-06-27 | 한국생명공학연구원 | GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024077085A1 (en) * | 2022-10-07 | 2024-04-11 | Memorial Sloan-Kettering Cancer Center | Targeting phospholipase a2 (pla2) in cancer |
| US12314787B2 (en) | 2023-04-27 | 2025-05-27 | Hewlett Packard Enterprise Development Lp | Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017671A1 (en) * | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| AU2012240154A1 (en) * | 2011-04-06 | 2013-10-17 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| CN102166364A (zh) * | 2011-04-14 | 2011-08-31 | 江南大学 | 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂 |
| MX2016010213A (es) * | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| US20190142835A1 (en) * | 2017-11-14 | 2019-05-16 | Oregon Health & Science University | Inhibition of autophagy using phospholipase a2 inhibitors |
-
2020
- 2020-07-15 WO PCT/US2020/042162 patent/WO2021011674A1/en not_active Ceased
- 2020-07-15 AU AU2020315388A patent/AU2020315388A1/en not_active Abandoned
- 2020-07-15 CN CN202080063214.7A patent/CN114364377A/zh active Pending
- 2020-07-15 US US17/626,370 patent/US20220257599A1/en not_active Abandoned
- 2020-07-15 EP EP20841099.3A patent/EP3999049A4/en not_active Withdrawn
- 2020-07-15 JP JP2022502559A patent/JP2022540921A/ja active Pending
- 2020-07-15 CA CA3147588A patent/CA3147588A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220257599A1 (en) | 2022-08-18 |
| WO2021011674A1 (en) | 2021-01-21 |
| EP3999049A4 (en) | 2023-07-26 |
| CN114364377A (zh) | 2022-04-15 |
| CA3147588A1 (en) | 2021-01-21 |
| JP2022540921A (ja) | 2022-09-20 |
| EP3999049A1 (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nguyen et al. | HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models | |
| Singh et al. | Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway | |
| Pathak et al. | Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis | |
| EP2965763B1 (en) | Anti-aging agents | |
| US20220257599A1 (en) | Methods useful in treating cancers harboring a kras or hras mutation or amplification | |
| KR101928543B1 (ko) | 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물 | |
| WO2016055533A1 (en) | 17a,21-diesters of cortexolone for use in the treatment of tumors | |
| Chao et al. | Phyto-sesquiterpene lactone deoxyelephantopin and cisplatin synergistically suppress lung metastasis of B16 melanoma in mice with reduced nephrotoxicity | |
| CN106715436A (zh) | 用于癌症治疗的小分子抑制剂 | |
| KR102000425B1 (ko) | 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물 | |
| US20220288130A1 (en) | Compositions and methods for diagnosis and treatment of metabolic diseases and disorders | |
| WO2016076359A1 (ja) | イベルメクチン又はミルベマイシンdを有効成分として含む抗癌剤 | |
| AU2022210355A1 (en) | Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity | |
| Peng et al. | mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat | |
| Zhao et al. | Induction of apoptosis by 5, 7-dihydroxy-8-nitrochrysin in breast cancer cells: the role of reactive oxygen species and Akt | |
| WO2024081428A2 (en) | Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer | |
| Feng et al. | HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein | |
| Wei et al. | Study on the mechanism of solasonine inhibiting the proliferation of oral squamous cell carcinoma based on lipidomics | |
| Fontana | Linking metabolic reprogramming to chemo-immuno-resistance: identifying new predictive biomarkers and druggable targets moving from OMIC techniques to single cell analysis | |
| US20240000977A1 (en) | Methods and kits for diagnosing and treating cancers | |
| Yang et al. | PLA2G16 deficiency enhances oxaliplatin sensitivity in colorectal cancer | |
| Bogucka et al. | ER-phagy drives resistance to mitochondria-targeted therapy in breast cancer | |
| Paoli | OPA1-driven cristae remodeling promotes pancreatic cancer progression | |
| Yi et al. | Cyclomulberrin represses renal cell carcinoma progression via ferroptosis activation | |
| 김성훈 | Protective effects of 17-oxo-docosahexaenoic acid and taurine chloramine on experimentally induced inflammation and carcinogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |